GPhA Commends Launch of Bipartisan Affordable Medicines Caucus

Published Online: Friday, May 2, 2014
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (May 2, 2014) — The Generic Pharmaceutical Association (GPhA) applauds the launch of the bipartisan Affordable Medicines Caucus, co-chaired by Representative Peter Welch (D-VT) and Representative Keith Rothfus (R-PA). GPhA and its members look forward to working with the Caucus to support its mission to educate patients and policymakers on the critical role of affordable generic medicines in holding down health costs.

“Members of both parties agree: taking full advantage of generic medicines is a common sense way to save billions of dollars for the government, and for millions of Americans.” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association. “Indeed, an IMS health analysis released by GPhA in December 2013 showed that generic pharmaceuticals have achieved $1.2 trillion in savings over the past decade, nearly $217 billion in 2012 alone, all of which translates to more than one billion dollars in savings every other day.”

The Caucus will share the newest information on the positive impact of generics on cost savings and help legislators track the latest developments in the field. Armed with this knowledge, lawmakers can make informed decisions about the future of healthcare policy.

“Working together,” said Neas, “we can build on the tremendous 30-year track record of bipartisan cooperation that has resulted in unprecedented access to safe, affordable, and life-changing generic medicines in America and around the world.”

Related Articles
The Generic Pharmaceutical Association welcomes the FDA’s proposed rule to amend its prescription drug and biological product labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals.
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Latest Issues
$auto_registration$